These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 7951238)

  • 1. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype.
    Saxena R; Shaw GL; Relling MV; Frame JN; Moir DT; Evans WE; Caporaso N; Weiffenbach B
    Hum Mol Genet; 1994 Jun; 3(6):923-6. PubMed ID: 7951238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
    Broly F; Meyer UA
    Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype.
    Marez D; Sabbagh N; Legrand M; Lo-Guidice JM; Boone P; Broly F
    Pharmacogenetics; 1995 Oct; 5(5):305-11. PubMed ID: 8563771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.
    Steen VM; Andreassen OA; Daly AK; Tefre T; Børresen AL; Idle JR; Gulbrandsen AK
    Pharmacogenetics; 1995 Aug; 5(4):215-23. PubMed ID: 8528268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype.
    Tyndale R; Aoyama T; Broly F; Matsunaga T; Inaba T; Kalow W; Gelboin HV; Meyer UA; Gonzalez FJ
    Pharmacogenetics; 1991 Oct; 1(1):26-32. PubMed ID: 1844820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine.
    Marez D; Legrand M; Sabbagh N; Lo-Guidice JM; Boone P; Broly F
    Hum Genet; 1996 May; 97(5):668-70. PubMed ID: 8655150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
    Evans WE; Relling MV
    Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution.
    Daly AK; Leathart JB; London SJ; Idle JR
    Hum Genet; 1995 Mar; 95(3):337-41. PubMed ID: 7868129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine.
    Evert B; Griese EU; Eichelbaum M
    Naunyn Schmiedebergs Arch Pharmacol; 1994 Oct; 350(4):434-9. PubMed ID: 7845481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cloning and sequencing of a new non-functional CYP2D6 allele: deletion of T1795 in exon 3 generates a premature stop codon.
    Evert B; Griese EU; Eichelbaum M
    Pharmacogenetics; 1994 Oct; 4(5):271-4. PubMed ID: 7894499
    [No Abstract]   [Full Text] [Related]  

  • 11. Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene.
    Steen VM; Molven A; Aarskog NK; Gulbrandsen AK
    Hum Mol Genet; 1995 Dec; 4(12):2251-7. PubMed ID: 8634695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis.
    Broly F; Marez D; Sabbagh N; Legrand M; Millecamps S; Lo Guidice JM; Boone P; Meyer UA
    Pharmacogenetics; 1995 Dec; 5(6):373-84. PubMed ID: 8747409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism.
    Douglas AM; Atchison BA; Somogyi AA; Drummer OH
    Pharmacogenetics; 1994 Jun; 4(3):154-8. PubMed ID: 7920695
    [No Abstract]   [Full Text] [Related]  

  • 14. Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population.
    Mura C; Gerard N; Vincent-Viry M; Galteau MM; Jacqz-Aigrain E; Krishnamoorthy R
    Br J Clin Pharmacol; 1993 Feb; 35(2):161-5. PubMed ID: 8095148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes.
    Kagimoto M; Heim M; Kagimoto K; Zeugin T; Meyer UA
    J Biol Chem; 1990 Oct; 265(28):17209-14. PubMed ID: 2211621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.
    Kimura S; Umeno M; Skoda RC; Meyer UA; Gonzalez FJ
    Am J Hum Genet; 1989 Dec; 45(6):889-904. PubMed ID: 2574001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
    Johansson I; Lundqvist E; Bertilsson L; Dahl ML; Sjöqvist F; Ingelman-Sundberg M
    Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11825-9. PubMed ID: 7903454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An unequal cross-over event within the CYP2D gene cluster generates a chimeric CYP2D7/CYP2D6 gene which is associated with the poor metabolizer phenotype.
    Panserat S; Mura C; Gérard N; Vincent-Viry M; Galteau MM; Jacoz-Aigrain E; Krishnamoorthy R
    Br J Clin Pharmacol; 1995 Oct; 40(4):361-7. PubMed ID: 8554938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
    Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Pelkonen O; Vainio H
    Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
    Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
    DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.